Literature DB >> 6222283

Defective monocyte chemotaxis in children with Down's syndrome.

O Barroeta, L Nungaray, M López-Osuna, S Armendares, F Salamanca, R R Kretschmer.   

Abstract

Under-agarose random migration, chemokinesis and chemotaxis of monocytes from 36 patients with Down's syndrome were compared to those of monocytes from 42 healthy, age-matched control children. Random migration of monocytes from patients with Down's syndrome was comparable to that of controls. In contrast, chemotaxis of monocytes from patients with Down's syndrome was significantly decreased (P less than 0.001) when compared to that of controls, even though chemokinesis was significantly increased (P less than 0.001). Age, sex, and physical development of patients with Down's syndrome or of control children included in this study had no apparent effect upon monocyte mobility.

Entities:  

Mesh:

Year:  1983        PMID: 6222283     DOI: 10.1203/00006450-198304000-00013

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  4 in total

1.  Altered monocyte function in patients with benign breast disease.

Authors:  A M Al-Sumidaie; S J Leinster; S A Jenkins
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

Review 2.  Infections and immunodeficiency in Down syndrome.

Authors:  G Ram; J Chinen
Journal:  Clin Exp Immunol       Date:  2011-02-24       Impact factor: 4.330

Review 3.  Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome.

Authors:  Tomer Illouz; Arya Biragyn; Maria Florencia Iulita; Lisi Flores-Aguilar; Mara Dierssen; Ilario De Toma; Stylianos E Antonarakis; Eugene Yu; Yann Herault; Marie-Claude Potier; Alexandra Botté; Randall Roper; Benjamin Sredni; Jacqueline London; William Mobley; Andre Strydom; Eitan Okun
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

Review 4.  Inflammation as a Modulator of Host Susceptibility to Pulmonary Influenza, Pneumococcal, and Co-Infections.

Authors:  Elizabeth R Aguilera; Laurel L Lenz
Journal:  Front Immunol       Date:  2020-02-11       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.